Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Short Interest Up 53.7% in July
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Short Interest Up 53.7% in July
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 13,200,000 shares, an increase of 53.7% from the July 15th total of 8,590,000 shares. Based on an average trading volume of 31,420,000 shares, the days-to-cover ratio is currently 0.4 days.
阿莱纳制药公司(纳斯达克代码：ALNA-GET评级)是7月份空头股数大幅增长的接受者。截至7月31日，空头股数共有1320万股，比7月15日的859万股增长了53.7%。以平均成交量31,420,000股计算，目前天数与回补比率为0.4天。
Allena Pharmaceuticals Stock Performance
Allena制药公司股票表现
Shares of NASDAQ:ALNA opened at $0.12 on Friday. The firm has a fifty day moving average price of $0.14 and a 200 day moving average price of $0.23. Allena Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $1.17.
纳斯达克股价：Alna上周五开盘报0.12美元。该公司的50日移动平均价为0.14美元，200日移动平均价为0.23美元。Allena PharmPharmticals的股价为52周低点0.07美元，52周高点为1.17美元。
Allena Pharmaceuticals (NASDAQ:ALNA – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.07. Research analysts expect that Allena Pharmaceuticals will post -0.31 earnings per share for the current fiscal year.
阿莱纳制药(纳斯达克：ALNA-GET评级)最近一次发布季度收益报告是在5月16日(星期一)。该公司公布本季度每股收益(EPS)为0.13美元，比分析师普遍预期的0.20美元高出0.07美元。研究分析师预计，Allena制药公司本财年的每股收益将为0.31美元。
About Allena Pharmaceuticals
关于Allena制药公司
Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
Allena制药公司是一家生物制药公司，在美国发现、开发和商业化口服酶疗法，用于治疗罕见和严重的代谢和肾脏疾病患者。它的主要候选产品是ALLN-346，这是一种新型的尿酸降解酶，适用于晚期慢性肾脏疾病中的高尿酸血症和痛风患者。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于Allena制药的研究报告(Alna)
- 值得关注的两场重要的零售股大战
- MarketBeat：回顾中的一周2012-8-8
- 什么是WallStreetBets，他们的目标是什么股票？
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗？
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Allena PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Allena制药和相关公司的最新新闻和分析师评级的每日简要摘要。